The salubrious effect of tamoxifen [correction of Tamaxifen] on serum marker enzymes, glycoproteins, and lysosomal enzymes level in breast cancer woman.
Tumour markers correlate strongly with prognosis based on tumour burden and surgical resectability. If chemotherapy is extremely effective in certain stage of the disease, the sensitive marker may be of great use in monitoring disease response and drug treatment. Hence, this study was launched to evaluate the changes in tumour marker enzymes like lactate dehydrogenase (LDH), glutamate oxaloacetate transaminase (SGOT), glutamate pyruvate transaminase (SGPT), alkaline phosphatase, and acid phosphatase in before and after 3 and 6 months tamoxifen treated breast cancer patients. In addition, the changes in serum glycoproteins viz., hexose, hexosamine, and sialic acid and lysosomal enzymes such as N-acetyl-beta-D-glucosaminidase, beta-D-galactosidase, and beta-D-glucuronidase were analysed in these patients. These values were compared with their age matched healthy control subjects. At 6 months evaluation, the tamoxifen treated postmenopausal breast cancer women showed a statistically significant decreased (p < 0.001, 0.05 respectively) levels of LDH, SGOT, SGPT, alkaline and acid phosphatases than their baseline values. Similarly, the levels of hexose, hexosamine, and sialic acid and N-acetyl-beta-D-glucosaminidase, beta-D-galactosidase, and beta-D-glucuronidase were decreased significantly (p < 0.001) in tamoxifen received postmenopausal women. The result of this study suggested that tamoxifen potentially retard the metastasis of breast cancer as well as the bone demineralisation in postmenopausal breast cancer women. Thus, tamoxifen may also have its antitumour activity through its beneficial effects on tumour marker enzymes and serum proteins in breast cancer women.
Thangaraju
M
M
Department of Medical Biochemistry, Dr.ALMP-GIBMS, University of Madras, Tamilnadu, India.
Rameshbabu
J
J
Vasavi
H
H
Ilanchezhian
S
S
Vinitha
R
R
Sachdanandam
P
P
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood* / Q000378:metabolism*; D001943:Breast Neoplasms / Q000097:blood* / Q000737:chemistry / Q000628:therapy; D004798:Enzymes / Q000097:blood / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D006023:Glycoproteins / Q000097:blood / Q000187:drug effects*; D006801:Humans; D008247:Lysosomes / Q000737:chemistry / Q000187:drug effects*; D008875:Middle Aged; D013629:Tamoxifen / Q000494:pharmacology* / Q000627:therapeutic use
D014408:Biomarkers, Tumor; D004798:Enzymes; D006023:Glycoproteins; D013629:Tamoxifen